Randolph J. Noelle
Research Subjects
Randolph J. Noelle has a total of 284 co-authors. Here are the top co-authors by number of shared publications:
- Janet Louise Lines
Dartmouth College
51 shared publications - Chao Cheng
Department of Medicine, Baylor College of Medicine, Houston, TX, USA
28 shared publications - Isabelle Le Mercier
KSQ Therapeutics, 4 Maguire Road, Lexington, MA 02421
27 shared publications - Jiannan Li
Department of the General Surgery, Jilin University Second Hospital, Changchun, China
27 shared publications - Aurelien Sarde
Department of Microbiology and Immunology, Dartmouth Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire
25 shared publications - Mohamed ElTanbouly
Laboratory of Molecular Immunology, The Rockefeller University 1 , New York, NY
23 shared publications
Latest Publications
- Open Access
Characterization of Anti-Canine PD-1 Antibodies
Cancer is a leading cause of death in dogs, and incidence rates in dogs exceed those in humans. Current therapeutic options for canine cancer patients remain limited, with most treatments focused on palliative care. Immune checkpoint inhibitors such as anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies that have transformed cancer therapy and expanded the therapeutic options in humans could offer the same clinical benefit in canine cancer patients. This study details the engineering and functional characterization of mouse and chimeric mouse–canine anti-canine PD-1 (cPD-1) monoclonal antibodies. We demonstrate that anti-cPD-1 antibodies block the interaction between cPD-1 and its ligand cPD-L1, thereby inhibiting this immune signaling pathway. In a proof-of-concept study in seven companion canine cancer patients, intratumoral therapy with the lead anti-cPD-1 antibody (HugPetmab) was safe, well-tolerated, had no observed adverse events, and showed evidence of tumor control in a subset of injected tumors. These findings support the potential of HugPetmab antibody as an immunotherapeutic option for treating canine cancer patients.
Open AccessCharacterization of Anti-Canine PD-1 Antibodies
Cancer is a leading cause of death in dogs, and incidence rates in dogs exceed those in humans. Current therapeutic options for canine cancer patients remain limited, with most treatments focused on palliative care. Immune checkpoint inhibitors such as anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies that have transformed cancer therapy and expanded the therapeutic options in humans could offer the same clinical benefit in canine cancer patients. This study details the engineering and functional characterization of mouse and chimeric mouse–canine anti-canine PD-1 (cPD-1) monoclonal antibodies. We demonstrate that anti-cPD-1 antibodies block the interaction between cPD-1 and its ligand cPD-L1, thereby inhibiting this immune signaling pathway. In a proof-of-concept study in seven companion canine cancer patients, intratumoral therapy with the lead anti-cPD-1 antibody (HugPetmab) was safe, well-tolerated, had no observed adverse events, and showed evidence of tumor control in a subset of injected tumors. These findings support the potential of HugPetmab antibody as an immunotherapeutic option for treating canine cancer patients.
- Open Access
- 18 February 2026
- Published by Elsevier in Cell Reports
- Vol. 45 (3) , 116980
Heterogeneity and plasticity of the naive CD4+ T cell compartment
- 18 February 2026
- Published by Elsevier in Cell Reports
- Vol. 45 (3) , 116980
Open AccessHeterogeneity and plasticity of the naive CD4+ T cell compartment
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance
Quality control and cluster identification of CD45-enriched scRNAseq data. In the I/V model, BALB/c mice were administered 100k CT26 cells and treated when tumors reached a size of 40mm3 with isotype (I) or anti-VISTA (V). In the CPV model, BALB/c mice were administered 100k CT26 cells and treated with anti-CTLA-4 and anti-PD-1 plus isotype (CP) or plus anti-VISTA (CPV) when tumors reached a size of 600mm3. In both models, CD45+ cells were isolated from the TME and analyzed by scRNAseq. (A) Histogram of the number of reads (left) and the number of genes (right) detected in all cells within the I/V dataset. (B) Histogram of the number of reads (left) and the number of genes (right) detected in all cells within the CP/CPV dataset. (C) Visual representation of lymphoid and myeloid cell distributions between experimental replicates using UMAP plots. (D) Expected and observed Local Inverse Simpson’s Index (LISI) measuring the degree of mixing among datasets. The LISI score ranges from 1 in an unmixed space to 2 in a perfectly mixed space with equal numbers of cells in each dataset. (E) AUCs calculated based on fivefold cross-validation where cells from each cluster are split into training and test datasets, a logistic regression classifier is trained on the training dataset and applied to the test dataset to measure model accuracy for each cluster. Higher AUC values correspond to better cluster discrimination. (F) Comparison of the number of cells detected per cluster in the I/V and CP/CPV datasets. (G) Comparison of the number of genes detected per cluster. (H) UMAP of all CD45+ cells sorted from I/V- and CP/CPV-treated tumor infiltrates, colored by cell cluster based on Louvain clustering. (I) Dot plots of cluster-defining marker genes for cell type annotations (as in H). Dot size represents fraction of cells expressing a gene in each cluster. Dot color represents scaled average expression by gene column.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance
Quality control and cluster identification of CD45-enriched scRNAseq data. In the I/V model, BALB/c mice were administered 100k CT26 cells and treated when tumors reached a size of 40mm3 with isotype (I) or anti-VISTA (V). In the CPV model, BALB/c mice were administered 100k CT26 cells and treated with anti-CTLA-4 and anti-PD-1 plus isotype (CP) or plus anti-VISTA (CPV) when tumors reached a size of 600mm3. In both models, CD45+ cells were isolated from the TME and analyzed by scRNAseq. (A) Histogram of the number of reads (left) and the number of genes (right) detected in all cells within the I/V dataset. (B) Histogram of the number of reads (left) and the number of genes (right) detected in all cells within the CP/CPV dataset. (C) Visual representation of lymphoid and myeloid cell distributions between experimental replicates using UMAP plots. (D) Expected and observed Local Inverse Simpson’s Index (LISI) measuring the degree of mixing among datasets. The LISI score ranges from 1 in an unmixed space to 2 in a perfectly mixed space with equal numbers of cells in each dataset. (E) AUCs calculated based on fivefold cross-validation where cells from each cluster are split into training and test datasets, a logistic regression classifier is trained on the training dataset and applied to the test dataset to measure model accuracy for each cluster. Higher AUC values correspond to better cluster discrimination. (F) Comparison of the number of cells detected per cluster in the I/V and CP/CPV datasets. (G) Comparison of the number of genes detected per cluster. (H) UMAP of all CD45+ cells sorted from I/V- and CP/CPV-treated tumor infiltrates, colored by cell cluster based on Louvain clustering. (I) Dot plots of cluster-defining marker genes for cell type annotations (as in H). Dot size represents fraction of cells expressing a gene in each cluster. Dot color represents scaled average expression by gene column.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance
Additional data supporting Figure 3. (A) Pathway enrichment for each cluster described in figure 3. (B) Comparison of myeloid clusters from this study with those identified by [30]. Dots represent the proportion of myeloid clusters described in this study (bottom) in the Gubin et al. myeloid clusters (left). Each row is normalized by row sums. Cluster identity from [30] was obtained from the original publication. (C) Cluster frequencies as a proportion of the myeloid infiltrate in I/V or CP/CPV treatment.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance
Additional data supporting Figure 3. (A) Pathway enrichment for each cluster described in figure 3. (B) Comparison of myeloid clusters from this study with those identified by [30]. Dots represent the proportion of myeloid clusters described in this study (bottom) in the Gubin et al. myeloid clusters (left). Each row is normalized by row sums. Cluster identity from [30] was obtained from the original publication. (C) Cluster frequencies as a proportion of the myeloid infiltrate in I/V or CP/CPV treatment.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance
Supplementary Figure S3. Anti-VISTA-induced changes to tumor-infiltrating immune cells in MB49. B6 mice were injected intra-dermally with 100k MB49 cells and treated when tumors reached a size of 100mm3 with isotype (I) or anti-VISTA (V). (A) Macrophage to monocyte ratio as determined by flow cytometry (B) Macrophage (CD45+, CD11b+, Gr1-, F4/80hi) frequency per gram of tumor as determined by flow cytometry. Expression of iNOS (C), MHC-II (D), and CD40 (E), was determined on CD45+, CD11b+, Gr1-, F4/80+ macrophages by flow cytometry. (F) CD40 expression within granulocytes (CD45+, CD11b+, Ly6G+, F4/80-) as determined by flow cytometry. Data are represented as mean ± SD. *P < 0.05.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance
Supplementary Figure S3. Anti-VISTA-induced changes to tumor-infiltrating immune cells in MB49. B6 mice were injected intra-dermally with 100k MB49 cells and treated when tumors reached a size of 100mm3 with isotype (I) or anti-VISTA (V). (A) Macrophage to monocyte ratio as determined by flow cytometry (B) Macrophage (CD45+, CD11b+, Gr1-, F4/80hi) frequency per gram of tumor as determined by flow cytometry. Expression of iNOS (C), MHC-II (D), and CD40 (E), was determined on CD45+, CD11b+, Gr1-, F4/80+ macrophages by flow cytometry. (F) CD40 expression within granulocytes (CD45+, CD11b+, Ly6G+, F4/80-) as determined by flow cytometry. Data are represented as mean ± SD. *P < 0.05.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance
Supplementary Figure S4. Additional data supporting Figure 6. In the I/V model, BALB/c mice were administered 100k CT26 cells and treated when tumors reached a size of 40mm3 with isotype (I) or anti-VISTA (V). In the CPV model, BALB/c mice were administered 100k CT26 cells and treated with anti-CTLA-4 and anti-PD-1 plus isotype (CP) or plus anti-VISTA (CPV) when tumors reached a size of 600mm3. CD45 + (A-C, E) or CD8+ AH1-tetramer+ (D) cells were isolated from the TME and analyzed by scRNAseq. (A) Stacked bar graph showing all lymphoid cluster frequencies as a proportion of the lymphoid infiltrate for I/V and CP/CPV. (B) Stacked bar graph showing NK cluster frequencies as a proportion of the NK infiltrate for I/V and CP/CPV. (C) Stacked bar graph showing CD8+ T cell cluster frequencies as a proportion of the CD8+ T cell infiltrate for I/V and CP/CPV. (D) Mean cluster frequencies as a proportion of CD8+ AH1-tetramer+ T cells in I/V or CP/CPV treatment. (E) Violin plots showing enrichment of a quiescence gene signature in CD8+ T cell clusters in the CD45 + sorted I/V dataset[58]. *P < 0.05, **P < 0.01, ***P < 0.001.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance
Supplementary Figure S4. Additional data supporting Figure 6. In the I/V model, BALB/c mice were administered 100k CT26 cells and treated when tumors reached a size of 40mm3 with isotype (I) or anti-VISTA (V). In the CPV model, BALB/c mice were administered 100k CT26 cells and treated with anti-CTLA-4 and anti-PD-1 plus isotype (CP) or plus anti-VISTA (CPV) when tumors reached a size of 600mm3. CD45 + (A-C, E) or CD8+ AH1-tetramer+ (D) cells were isolated from the TME and analyzed by scRNAseq. (A) Stacked bar graph showing all lymphoid cluster frequencies as a proportion of the lymphoid infiltrate for I/V and CP/CPV. (B) Stacked bar graph showing NK cluster frequencies as a proportion of the NK infiltrate for I/V and CP/CPV. (C) Stacked bar graph showing CD8+ T cell cluster frequencies as a proportion of the CD8+ T cell infiltrate for I/V and CP/CPV. (D) Mean cluster frequencies as a proportion of CD8+ AH1-tetramer+ T cells in I/V or CP/CPV treatment. (E) Violin plots showing enrichment of a quiescence gene signature in CD8+ T cell clusters in the CD45 + sorted I/V dataset[58]. *P < 0.05, **P < 0.01, ***P < 0.001.
- Open Access
- 10 January 2025
- Published by Springer Nature in Research Square
Heterogeneity and plasticity of the naïve CD4+ T cell compartment
While naïve CD4+ T cells have historically been considered a homogenous population, recent studies have provided evidence that functional heterogeneity exists within this population. Using single cell RNA sequencing (scRNAseq), we identify five transcriptionally distinct naïve CD4+ T cell subsets that emerge within the single positive stage in the thymus: a quiescence cluster (TQ), a memory-like cluster (TMEM), a TCR reactive cluster (TTCR), an IFN responsive cluster (TIFN), and an undifferentiated cluster (TUND). Elevated expression of transcription factors KLF2, Mx1, and Nur77 within the TQ, TIFN, and TMEM clusters, respectively, allowed enrichment of these subsets for further analyses. Functional studies using sorted cells revealed that naïve T cell subsets have distinctive functional biases upon stimulation. Furthermore, treatment of mice with inflammatory stimuli imparted a state of reduced responsiveness on naïve T cells, evidenced by a reduction in cytokine production ex vivo. In human lupus patients, naïve CD4+ T cell cluster frequencies were distorted, with the TIFN cluster expanding proportionately with disease score. Our data show that naïve T cells are influenced by host environment, with functional consequences manifesting upon activation. These findings highlight a need to explore how naïve T cells can become distorted in cancer, autoimmunity, and infectious diseases.
- 10 January 2025
- Published by Springer Nature in Research Square
Open AccessHeterogeneity and plasticity of the naïve CD4+ T cell compartment
While naïve CD4+ T cells have historically been considered a homogenous population, recent studies have provided evidence that functional heterogeneity exists within this population. Using single cell RNA sequencing (scRNAseq), we identify five transcriptionally distinct naïve CD4+ T cell subsets that emerge within the single positive stage in the thymus: a quiescence cluster (TQ), a memory-like cluster (TMEM), a TCR reactive cluster (TTCR), an IFN responsive cluster (TIFN), and an undifferentiated cluster (TUND). Elevated expression of transcription factors KLF2, Mx1, and Nur77 within the TQ, TIFN, and TMEM clusters, respectively, allowed enrichment of these subsets for further analyses. Functional studies using sorted cells revealed that naïve T cell subsets have distinctive functional biases upon stimulation. Furthermore, treatment of mice with inflammatory stimuli imparted a state of reduced responsiveness on naïve T cells, evidenced by a reduction in cytokine production ex vivo. In human lupus patients, naïve CD4+ T cell cluster frequencies were distorted, with the TIFN cluster expanding proportionately with disease score. Our data show that naïve T cells are influenced by host environment, with functional consequences manifesting upon activation. These findings highlight a need to explore how naïve T cells can become distorted in cancer, autoimmunity, and infectious diseases.
- Open Access
Heterogeneity and plasticity of the naïve CD4 + T cell compartment
While naïve CD4 + T cells have historically been considered a homogenous population, recent studies have provided evidence that functional heterogeneity exists within this population. Using single cell RNA sequencing (scRNAseq), we identify five transcriptionally distinct naïve CD4 + T cell subsets that emerge within the single positive stage in the thymus: a quiescence cluster (T Q ), a memory-like cluster (T MEM ), a TCR reactive cluster (T TCR ), an IFN responsive cluster (T IFN ), and an undifferentiated cluster (T UND ). Elevated expression of transcription factors KLF2, Mx1, and Nur77 within the T Q , T IFN , and T MEM clusters, respectively, allowed enrichment of these subsets for further analyses. Functional studies using sorted cells revealed that naïve T cell subsets have distinctive functional biases upon stimulation. Furthermore, treatment of mice with inflammatory stimuli imparted a state of reduced responsiveness on naïve T cells, evidenced by a reduction in cytokine production ex vivo . In human lupus patients, naïve CD4 + T cell cluster frequencies were distorted, with the T IFN cluster expanding proportionately with disease score. Our data show that naïve T cells are influenced by host environment, with functional consequences manifesting upon activation. These findings highlight a need to explore how naïve T cells can become distorted in cancer, autoimmunity, and infectious diseases. Summary: This study describes the transcriptional heterogeneity of murine and human naïve CD4 + T cells as comprising of multiple discrete clusters that impact CD4 + T cell fate and trajectories. Naïve CD4 + T cells experiencing inflammatory environments exhibit an altered transcriptional state that influences their functional trajectory.
Open AccessHeterogeneity and plasticity of the naïve CD4 + T cell compartment
While naïve CD4 + T cells have historically been considered a homogenous population, recent studies have provided evidence that functional heterogeneity exists within this population. Using single cell RNA sequencing (scRNAseq), we identify five transcriptionally distinct naïve CD4 + T cell subsets that emerge within the single positive stage in the thymus: a quiescence cluster (T Q ), a memory-like cluster (T MEM ), a TCR reactive cluster (T TCR ), an IFN responsive cluster (T IFN ), and an undifferentiated cluster (T UND ). Elevated expression of transcription factors KLF2, Mx1, and Nur77 within the T Q , T IFN , and T MEM clusters, respectively, allowed enrichment of these subsets for further analyses. Functional studies using sorted cells revealed that naïve T cell subsets have distinctive functional biases upon stimulation. Furthermore, treatment of mice with inflammatory stimuli imparted a state of reduced responsiveness on naïve T cells, evidenced by a reduction in cytokine production ex vivo . In human lupus patients, naïve CD4 + T cell cluster frequencies were distorted, with the T IFN cluster expanding proportionately with disease score. Our data show that naïve T cells are influenced by host environment, with functional consequences manifesting upon activation. These findings highlight a need to explore how naïve T cells can become distorted in cancer, autoimmunity, and infectious diseases. Summary: This study describes the transcriptional heterogeneity of murine and human naïve CD4 + T cells as comprising of multiple discrete clusters that impact CD4 + T cell fate and trajectories. Naïve CD4 + T cells experiencing inflammatory environments exhibit an altered transcriptional state that influences their functional trajectory.
- Open Access
An Abscopal Effect on Lung Metastases in Canine Mammary Cancer Patients Induced by Neoadjuvant Intratumoral Immunotherapy with Cowpea Mosaic Virus Nanoparticles and Anti-Canine PD-1
Neoadjuvant intratumoral (IT) therapy could amplify the weak responses to checkpoint blockade therapy observed in breast cancer (BC). In this study, we administered neoadjuvant IT anti-canine PD-1 therapy (IT acPD-1) alone or combined with IT cowpea mosaic virus therapy (IT CPMV/acPD-1) to companion dogs diagnosed with canine mammary cancer (CMC), a spontaneous tumor resembling human BC. CMC patients treated weekly with acPD-1 (n = 3) or CPMV/acPD-1 (n = 3) for four weeks or with CPMV/acPD-1 (n = 3 patients not candidates for surgery) for up to 11 weeks did not experience immune-related adverse events. We found that acPD-1 and CPMV/acPD-1 injections resulted in tumor control and a reduction in injected tumors in all patients and in noninjected tumors located in the ipsilateral and contralateral mammary chains of treated dogs. In two metastatic CMC patients, CPMV/acPD-1 treatments resulted in the control and reduction of established lung metastases. CPMV/acPD-1 treatments were associated with altered gene expression related to TLR1–4 signaling and complement pathways. These novel therapies could be effective for CMC patients. Owing to the extensive similarities between CMC and human BC, IT CPMV combined with approved anti-PD-1 therapies could be a novel and effective immunotherapy to treat local BC and suppress metastatic BC.
Open AccessAn Abscopal Effect on Lung Metastases in Canine Mammary Cancer Patients Induced by Neoadjuvant Intratumoral Immunotherapy with Cowpea Mosaic Virus Nanoparticles and Anti-Canine PD-1
Neoadjuvant intratumoral (IT) therapy could amplify the weak responses to checkpoint blockade therapy observed in breast cancer (BC). In this study, we administered neoadjuvant IT anti-canine PD-1 therapy (IT acPD-1) alone or combined with IT cowpea mosaic virus therapy (IT CPMV/acPD-1) to companion dogs diagnosed with canine mammary cancer (CMC), a spontaneous tumor resembling human BC. CMC patients treated weekly with acPD-1 (n = 3) or CPMV/acPD-1 (n = 3) for four weeks or with CPMV/acPD-1 (n = 3 patients not candidates for surgery) for up to 11 weeks did not experience immune-related adverse events. We found that acPD-1 and CPMV/acPD-1 injections resulted in tumor control and a reduction in injected tumors in all patients and in noninjected tumors located in the ipsilateral and contralateral mammary chains of treated dogs. In two metastatic CMC patients, CPMV/acPD-1 treatments resulted in the control and reduction of established lung metastases. CPMV/acPD-1 treatments were associated with altered gene expression related to TLR1–4 signaling and complement pathways. These novel therapies could be effective for CMC patients. Owing to the extensive similarities between CMC and human BC, IT CPMV combined with approved anti-PD-1 therapies could be a novel and effective immunotherapy to treat local BC and suppress metastatic BC.